Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n = 400) could be optimized by doubling the dose (n = 420), adding interferon (IFN) (n = 430) or cytarabine (n = 158) or using IM after IFN-failure (n = 128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hehlmann, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lauseker, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Saussele, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfirrmann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krause, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolb, H. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neubauer, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hossfeld, D. K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nerl, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gratwohl, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baerlocher, G. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heim, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bruemmendorf, T. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fabarius, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haferlach, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlegelberger, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, M. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jeromin, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Proetel, U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kohlbrenner, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Voskanyan, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rinaldetti, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seifarth, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spiess, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Balleisen, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goebeler, M. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haenel, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ho, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dengler, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Falge, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kanz, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kremers, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Burchert, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kneba, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stegelmann, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Koehne, C. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lindemann, H. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waller, C. F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfreundschuh, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Spiekermann, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Berdel, W. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Edinger, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beelen, D. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bentz, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Link, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hertenstein, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wernli, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlegel, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlag, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Wit, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Truemper, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hebart, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hahn, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomalla, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schafhausen, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Verbeek, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eckart, M. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gassmann, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pezzutto, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schenk, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brossart, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geer, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bildat, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaefer, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hochhaus, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hasford, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-213598
DOI: 10.1038/leu.2017.253
Journal or Publication Title: Leukemia
Volume: 31
Number: 11
Page Range: S. 2398 - 2407
Date: 2017
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
KINASE INHIBITOR OPTIMIZATION; MOLECULAR RESPONSE; 800 MG; EXPERT PANEL; END-POINTS; OPEN-LABEL; RECOMMENDATIONS; INTERFERON; PROGNOSIS; RISKMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/21359

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item